Everest Medicines expands portfolio with Sumecigrel in Asia-Pacific

China-based Everest Medicines has entered an exclusive licensing agreement with Jiangsu Vcare PharmaTech Co., for the development, registration and commercialisation of Sumecigrel across the Asia-Pacific region. The deal covers Southeast Asia, South Korea, Australia, Hong Kong SAR, Macao SAR, and Taiwan region, China.

Financial Terms of the Deal

Pursuant to the agreement, Everest Medicines will pay Vcare PharmaTech an upfront payment of RMB 20 million, along with subsequent milestone payments and commercial supply procurement. The filing notes that this collaboration strengthens the company’s cardiovascular portfolio and highlights Everest’s continued focus on the Asia-Pacific market, supporting the advancement of its regional strategy and the development of innovative therapies.

The Science Behind the Drug

Sumecigrel is an antiplatelet agent and a new-generation oral P2Y12 receptor antagonist. It is being clinically developed for the treatment and prevention of atherothrombotic events such as acute coronary syndrome (ACS), ischemic stroke (IS) and peripheral arterial disease (PAD). As a novel antithrombotic drug self-developed by Vcare PharmaTech, the product is currently advancing preparations for NDA in China, the United States, Europe.

As a next-generation P2Y12 receptor antagonist, Sumecigrel has completed Phase I, Phase II, China-US PK/PD bridging study and Phase III clinical trials. It has demonstrated favorable efficacy and safety with solid clinical value, and is poised to become an improved treatment option for patients with ACS, IS and PAD.

The agreement allows Everest Medicines to leverage a molecule that is already in late-stage testing, rather than starting from a clinical blank slate. This approach reduces the time required to bring a therapy to patients in the region, as the safety data from the trials conducted by Vcare PharmaTech can often support faster regulatory review in partner markets. By securing rights to a drug that has already shown consistent results in human subjects, Everest positions itself to fill gaps in its own pipeline with a product that has already passed the most difficult phases of development.

From a strategic perspective, this collaboration represents another important step in Everest Medicines’ ongoing efforts to deepen its presence across the Asia-Pacific region. The company is clearly prioritising markets where it can build on existing infrastructure while introducing new treatment classes.

Sumecigrel works by blocking the P2Y12 receptor on platelets, preventing them from sticking together. This mechanism addresses the core issue of thrombus formation, which causes many cardiovascular events.

Everest Medicines is expected to utilize Vcare PharmaTech’s existing safety data to accelerate the regulatory submission process in the Asia-Pacific territories. The agreement grants the partner rights to a molecule already in late-stage testing, reducing the risk and timeline associated with new drug development. The filing notes that the deal strengthens the company’s cardiovascular portfolio and highlights Everest’s continued focus on the Asia-Pacific market, supporting the advancement of its regional strategy and the development of innovative therapies.

Dual agonists break the pain safety trade-off.